Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer.

ABSTRACT: Breast cancer (BC) is a heterogeneous disease that can be molecularly classified based on the expression of the ERBB2 receptor (also known as HER2) and hormone receptors. Targeted therapies for HER2-positive BC, such as trastuzumab, antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors, have improved patient outcomes, but primary/acquired resistance still poses challenges that can limit treatments' long-term efficacy. Addressing these obstacles is vital for enhancing therapeutic strategies and patient care. Alternative splicing, a post-transcriptional mechanism that enhances transcript diversity (isoforms), can produce proteins with varied functions, cellular localizations, or binding properties. Here, we comprehensively characterize the HER2 alternative splicing iso

SUBMITTER: Guardia GDA 

PROVIDER: S-EPMC12400952 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature